WebTPS592 Background: For advanced CCA, standard of care 1L systemic treatment is GEM + CIS. Genetic alterations in intrahepatic CCA provide potential therapeutic targets. Fibroblast growth factor receptor (FGFR) 2 gene rearrangements driving CCA tumorigenesis were identified almost exclusively in intrahepatic CCA patients (pts) (incidence, 10–16%). In … WebFGFR2 rearrangements resulting in dysregulated signaling are drivers of cholangiocarcinoma (CCA) tumorigenesis, and occur almost exclusively in intrahepatic CCA. Pemigatinib, a selective, potent, oral inhibitor of FGFR1-3, has demonstrated efficacy and safety in a Phase II study of patients with pre …
Alcoholic liver disease and risk of cholangiocarcinoma: a …
WebIntroduction. Cholangiocarcinoma (CCA), as a kind of malignancy from the bile duct epithelium, 1 was first described by Durand-Fardel in 1840. Regarding incidence, CCA is the second among all the primary hepatocellular carcinoma (HCC), taking up 3% of all the gastrointestinal neoplasms 2,3 and 10%–25% of all the malignant HCCs. Besides, the … WebInfigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2024 Oct;6 (10):803-815. Epub 2024 Aug 3. link to original article PubMed. florida elected officials oath of office
Cisplatin plus gemcitabine versus gemcitabine for biliary ... - PubMed
WebOct 1, 2024 · Background: In this retrospective cohort study, the potential of gemcitabine (gem)/cisplatin (cis) chemotherapy as future preoperative therapy for patients with … WebOn September 2, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca UK Limited) in combination with gemcitabine and cisplatin for adult … WebFeb 10, 2024 · In a smaller preliminary clinical trial, Dr. Oh and her colleagues found that adding durvalumab to the standard gemcitabine–cisplatin combination showed promising antitumor activity as a first-line treatment for advanced biliary tract cancer. Those results were the basis for conducting a larger trial. florida e-filing portal telephone number